Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS. Preliminary imaging data showed encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions.
The company submitted an IND for a Phase 2 trial of Lucid-MS to the FDA in March 2026. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Multiple sclerosis affects approximately 2.8 million people worldwide, and current imaging techniques have limitations in detecting gray matter lesions and tracking remyelination.
This imaging milestone is significant because it could provide a more direct method to assess demyelination, a key pathological feature of MS. The tracer technology may also facilitate more efficient clinical trials by enabling earlier detection of treatment effects. The study's results could support the development of Lucid-MS and potentially other myelin-repair therapies.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders. Through its subsidiary Lucid Psycheceuticals Inc., it is developing Lucid-MS for MS. The company also holds a stake in Unbuzzd Wellness Inc., which markets an OTC product for alcohol misuse. More information is available in the company's newsroom at https://ibn.fm/QNTM.
For details on the imaging study, refer to the full press release at https://ibn.fm/4IZ0y.
